The O
evidence O
of O
a O
significant O
proportion O
of O
loss O
- O
of O
- O
function O
mutations O
and O
a O
complete O
absence O
of O
the O
normal O
copy O
of O
ATM O
in O
the O
majority O
of O
mutated O
tumours B
establishes O
somatic O
inactivation O
of O
this O
gene O
in O
the O
pathogenesis O
of O
sporadic B
T I
- I
PLL I
and O
suggests O
that O
ATM O
acts O
as O
a O
tumour B
suppressor O
. O

Germ O
- O
line O
mutations O
of O
the O
BRCA1 O
gene O
predispose O
women O
to O
early O
- O
onset O
breast B
and I
ovarian I
cancer I
by O
compromising O
the O
genes O
presumptive O
function O
as O
a O
tumor B
suppressor O
. O

Low O
frequency O
of O
BRCA1 O
germline O
mutations O
in O
45 O
German O
breast B
/ I
ovarian I
cancer I
families O
. O

In O
this O
study O
we O
investigated O
45 O
German O
breast B
/ I
ovarian I
cancer I
families O
for O
germline O
mutations O
in O
the O
BRCA1 O
gene O
. O

We O
identified O
four O
germline O
mutations O
in O
three O
breast B
cancer I
families O
and O
in O
one O
breast B
- I
ovarian I
cancer I
family O
. O
among O
these O
were O
one O
frameshift O
mutation O
, O
one O
nonsense O
mutation O
, O
one O
novel O
splice O
site O
mutation O
, O
and O
one O
missense O
mutation O
. O

These O
findings O
show O
that O
BRCA1 O
is O
implicated O
in O
a O
small O
fraction O
of O
breast B
/ I
ovarian I
cancer I
families O
suggesting O
the O
involvement O
of O
another O
susceptibility O
gene O
( O
s O
) O

The O
RB1 O
gene O
mutation O
was O
investigated O
in O
a O
child O
with O
ectopic B
intracranial I
retinoblastoma I
using O
DNA O
obtained O
from O
both O
the O
pineal B
and I
retinal I
tumours I
of O
the O
patient O
. O

Appreciable O
beta O
hexosaminidase O
A O
( O
hex O
A O
) O
activity O
has O
been O
detected O
in O
cultured O
skin O
fibroblasts O
and O
melanoma B
tissue O
from O
healthy O
individuals O
previously O
reported O
as O
having O
deficiency B
of I
hex I
A I
activity O
indistinguishable O
from O
that O
of O
patients O
with O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
. O

Appreciable O
beta O
hexosaminidase O
A O
( O
hex O
A O
) O
activity O
has O
been O
detected O
in O
cultured O
skin O
fibroblasts O
and O
melanoma B
tissue O
from O
healthy O
individuals O
previously O
reported O
as O
having O
deficiency B
of I
hex I
A I
activity O
indistinguishable O
from O
that O
of O
patients O
with O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
. O

Aspartylglucosaminuria B
( O
AGU B
) O
is O
a O
rare O
disorder B
of I
glycoprotein I
metabolism I
caused O
by O
the O
deficiency B
of I
the I
lysosomal I
enzyme I
aspartylglucosaminidase I
( O
AGA O
) O
. O

In O
combination O
with O
molecular O
genetic O
analyses O
, O
this O
test O
may O
be O
of O
value O
in O
studies O
of O
familial B
and I
sporadic I
cancers I
aimed O
at O
determination O
of O
the O
potential O
involvement O
of O
ATM O
mutations O
in O
tumor B
risk O
or O
development O
. O
. O

The O
inactivation O
of O
the O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
tumor I
suppressor O
gene O
predisposes O
affected O
individuals O
to O
the O
human O
VHL B
cancer I
syndrome I
and O
is O
associated O
with O
sporadic B
renal I
cell I
carcinomas I
( O
RCC B
) O
and O
brain B
hemangioblastomas I
. O

Cycloheximide O
facilitates O
the O
identification O
of O
aberrant O
transcripts O
resulting O
from O
a O
novel O
splice O
- O
site O
mutation O
in O
COL17A1 O
in O
a O
patient O
with O
generalized O
atrophic B
benign I
epidermolysis I
bullosa I
. O

Patients O
with O
generalized O
atrophic B
benign I
epidermolysis I
bullosa I
often O
show O
decreased O
expression O
of O
type O
XVII O
collagen O
, O
a O
transmembrane O
hemidesmosomal O
protein O
encoded O
by O
COL17A1 O
. O

This O
report O
documents O
a O
novel O
splice O
- O
site O
mutation O
in O
COL17A1 O
in O
a O
patient O
with O
generalized O
atrophic B
benign I
epidermolysis I
bullosa I
, O
and O
applies O
a O
new O
methodology O
to O
define O
and O
characterize O
the O
resulting O
mRNA O
splice O
variants O
. O

A O
deletion O
mutation O
in O
COL17A1 O
in O
five O
Austrian O
families O
with O
generalized O
atrophic B
benign I
epidermolysis I
bullosa I
represents O
propagation O
of O
an O
ancestral O
allele O
. O

Patients O
with O
generalized O
atrophic B
benign I
epidermolysis I
bullosa I
, O
a O
usually O
nonlethal O
form O
of O
junctional B
epidermolysis I
bullosa I
, O
have O
generalized O
blistering B
, O
nail B
dystrophy I
, O
patchy B
alopecia I
, O
and O
dental B
abnormalities I
. O

Recently O
, O
we O
reported O
five O
Austrian O
families O
with O
generalized O
atrophic B
benign I
epidermolysis I
bullosa I
who O
share O
the O
same O
COL17A1 O
mutation O
. O

Mutation O
spectrum O
and O
genotype O
- O
phenotype O
analyses O
in O
Cowden B
disease I
and O
Bannayan B
- I
Zonana I
syndrome I
, O
two O
hamartoma B
syndromes I
with O
germline O
PTEN O
mutation O
. O

Molecular O
defects O
leading O
to O
human O
complement B
component I
C6 I
deficiency I
in O
an O
African O
- O
American O
family O
. O

Complement B
component I
C6 I
deficiency I
( O
C6D B
) O
was O
diagnosed O
in O
a O
16 O
- O
year O
- O
old O
African O
- O
American O
male O
with O
meningococcal B
meningitis I
. O

Families O
were O
included O
without O
regard O
to O
the O
occurrence O
of O
ovarian B
or I
other I
cancers I
. O

The O
majority O
( O
81 O
% O
) O
of O
the O
breast B
- I
ovarian I
cancer I
families O
were O
due O
to O
BRCA1 O
, O
with O
most O
others O
( O
14 O
% O
) O
due O
to O
BRCA2 O
. O

Eye B
movement I
abnormalities I
correlate O
with O
genotype O
in O
autosomal O
dominant O
cerebellar B
ataxia I
type I
I I
. O

We O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B
ataxias I
type I
I I
spinocerebellar B
ataxias I
1 I
and I
2 I
( O
SCA1 B
, O
n O
= O
11 O
; O
SCA2 B
, O
n O
= O
10 O
) O
and O
SCA3 B
/ O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
( O
n O
= O
16 O
) O
. O

We O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B
ataxias I
type I
I I
spinocerebellar B
ataxias I
1 I
and I
2 I
( O
SCA1 B
, O
n O
= O
11 O
; O
SCA2 B
, O
n O
= O
10 O
) O
and O
SCA3 B
/ O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
( O
n O
= O
16 O
) O
. O

In O
SCA3 B
, O
gaze B
- I
evoked I
nystagmus I
was O
often O
present O
as O
was O
saccade O
hypometria O
and O
smooth O
pursuit O
gain O
was O
markedly O
decreased O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B
- I
evoked I
nystagmus I
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B
, O
90 O
% O
of O
the O
SCA2 B
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
SCA1 B
, O
SCA2 B
, O
and O
SCA3 B
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

Constitutional O
mutations O
of O
the O
WT1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
Denys B
- I
Drash I
syndrome I
( O
DDS B
) O
, O
or O
diffuse B
mesangial I
sclerosis I
( O
DMS B
) O
associated O
with O
pseudohermaphroditism B
and O
/ O
or O
Wilms B
tumor I
( O
WT B
) O
. O

BRCA1 O
allelic O
patterns O
were O
determined O
for O
four O
of O
these O
individuals O
and O
for O
12 O
additional O
non O
- O
Ashkenazi O
185delAG O
mutation O
carriers O
who O
had O
breast B
/ I
ovarian I
cancer I
. O

HFE O
is O
an O
MHC O
- O
related O
protein O
that O
is O
mutated O
in O
the O
iron B
- I
overload I
disease I
hereditary B
hemochromatosis I
. O

Identification O
of O
a O
novel O
nonsense O
mutation O
and O
a O
missense O
substitution O
in O
the O
vasopressin O
- O
neurophysin O
II O
gene O
in O
two O
Spanish O
kindreds O
with O
familial B
neurohypophyseal I
diabetes I
insipidus I
. O

Familial B
neurohypophyseal I
diabetes I
insipidus I
( O
FNDI B
) O
is O
an O
autosomal B
dominant I
disease I
caused O
by O
deficiency O
in O
the O
antidiuretic O
hormone O
arginine O
vasopressin O
( O
AVP O
) O
encoded O
by O
the O
AVP O
- O
neurophysin O
II O
( O
AVP O
- O
NPII O
) O
gene O
on O
chromosome O
20p13 O
. O

Genetic O
heterogeneity O
of O
Saethre B
- I
Chotzen I
syndrome I
, O
due O
to O
TWIST O
and O
FGFR O
mutations O
. O

Thirty O
- O
two O
unrelated O
patients O
with O
features O
of O
Saethre B
- I
Chotzen I
syndrome I
, O
a O
common O
autosomal B
dominant I
condition I
of O
craniosynostosis B
and O
limb B
anomalies I
, O
were O
screened O
for O
mutations O
in O
TWIST O
, O
FGFR2 O
, O
and O
FGFR3 O
. O

To O
date O
, O
our O
detection O
rate O
for O
TWIST O
or O
FGFR O
mutations O
is O
68 O
% O
in O
our O
Saethre B
- I
Chotzen I
syndrome I
patients O
, O
including O
our O
five O
patients O
elsewhere O
reported O
with O
TWIST O
mutations O
. O

Genotype O
- O
phenotype O
correlations O
in O
attenuated B
adenomatous I
polyposis I
coli I
. O

Germ O
- O
line O
mutations O
of O
the O
tumor B
suppressor O
APC O
are O
implicated O
in O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
, O
a O
variant O
of O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
. O

In O
contrast O
, O
WT1 O
missense O
mutations O
, O
associated O
with O
male B
pseudohermaphroditism I
in O
Denys B
- I
Drash I
syndrome I
, O
fail O
to O
synergize O
with O
SF O
- O
1 O
. O

A O
mouse O
model O
for O
Prader B
- I
Willi I
syndrome I
imprinting O
- O
centre O
mutations O
. O

Deletion O
of O
this O
IC O
abolishes O
local O
paternally O
derived O
gene O
expression O
and O
results O
in O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

Mutations O
in O
the O
HEXA O
gene O
, O
encoding O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
A O
( O
Hex O
A O
) O
, O
that O
abolish O
Hex O
A O
enzyme O
activity O
cause O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
, O
the O
fatal O
infantile B
form I
of I
G I
( I
M2 I
) I
gangliosidosis I
, I
Type I
1 I
. O

We O
conclude O
that O
the O
1422 O
G O
- O
- O
> O
C O
mutation O
is O
the O
cause O
of O
Hex B
A I
enzyme I
deficiency I
in O
the O
proband O
. O

Maternal B
disomy I
and O
Prader B
- I
Willi I
syndrome I
consistent O
with O
gamete O
complementation O
in O
a O
case O
of O
familial O
translocation O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
. O

Maternal B
uniparental I
disomy I
( I
UPD I
) I
for I
chromosome I
15 I
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

Schwartz B
- I
Jampel I
syndrome I
type I
2 I
and O
Stuve B
- I
Wiedemann I
syndrome I
: O
a O
case O
for O
" O
lumping O
" O
. O

Recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
) O
of O
myotonia B
and O
skeletal B
dysplasia I
, O
which O
we O
called O
SJS B
type I
2 I
. O

This O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
Stuve B
- I
Wiedemann I
syndrome I
( O
SWS B
) O
, O
which O
comprises O
campomelia B
at O
birth O
with O
skeletal B
dysplasia I
, O
contractures B
, O
and O
early B
death I
. O

The O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
encodes O
a O
zinc O
finger O
protein O
of O
unknown O
function O
. O

Classical O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
high O
- O
penetrance O
autosomal B
dominant I
disease I
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B
adenomas I
and I
carcinoma I
and O
that O
results O
from O
truncating O
mutations O
in O
the O
APC B
gene O
. O

A O
variant O
of O
FAP B
is O
attenuated B
adenomatous I
polyposis I
coli I
, O
which O
results O
from O
germ O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
APC B
gene O
. O

Attenuated B
adenomatous I
polyposis I
coli I
patients O
have O
" O
multiple O
" O
colorectal B
adenomas I
( O
typically O
fewer O
than O
100 O
) O
without O
the O
florid O
phenotype O
of O
classical O
FAP B
. O

There O
is O
increasing O
evidence O
that O
there O
exist O
germ O
- O
line O
variants O
of O
the O
APC B
gene O
that O
predispose O
to O
the O
development O
of O
multiple O
colorectal B
adenomas I
and I
carcinoma I
, O
but O
without O
the O
florid O
phenotype O
of O
classical O
FAP B
, O
and O
possibly O
with O
importance O
for O
colorectal B
cancer I
risk O
in O
the O
general O
population O
. O
. O

Deficiency B
of I
arylsulfatase I
A I
( O
ARSA O
) O
enzyme O
activity O
causes O
metachromatic B
leukodystrophy I
( O
MLD B
) O
. O

Down O
- O
regulation O
of O
transmembrane O
carbonic O
anhydrases O
in O
renal B
cell I
carcinoma I
cell O
lines O
by O
wild O
- O
type O
von B
Hippel I
- I
Lindau I
transgenes O
. O

Down O
- O
regulation O
of O
transmembrane O
carbonic O
anhydrases O
in O
renal B
cell I
carcinoma I
cell O
lines O
by O
wild O
- O
type O
von B
Hippel I
- I
Lindau I
transgenes O
. O

To O
discover O
genes O
involved O
in O
von B
Hippel I
- I
Lindau I
( O
VHL B
) O
- O
mediated O
carcinogenesis O
, O
we O
used O
renal B
cell I
carcinoma I
cell O
lines O
stably O
transfected O
with O
wild O
- O
type O
VHL O
- O
expressing O
transgenes O
. O

Wolfram B
syndrome I
( O
WFS B
; O
OMIM O
222300 O
) O
is O
an O
autosomal B
recessive I
neurodegenerative I
disorder I
defined O
by O
young O
- O
onset O
non O
- O
immune O
insulin B
- I
dependent I
diabetes I
mellitus I
and O
progressive O
optic B
atrophy I
. O

Determination O
of O
the O
genomic O
structure O
of O
the O
COL4A4 O
gene O
and O
of O
novel O
mutations O
causing O
autosomal B
recessive I
Alport I
syndrome I
. O

Autosomal B
recessive I
Alport I
syndrome I
is O
a O
progressive O
hematuric B
glomerulonephritis I
characterized O
by O
glomerular B
basement I
membrane I
abnormalities I
and O
associated O
with O
mutations O
in O
either O
the O
COL4A3 O
or O
the O
COL4A4 O
gene O
, O
which O
encode O
the O
alpha3 O
and O
alpha4 O
type O
IV O
collagen O
chains O
, O
respectively O
. O

Autosomal B
recessive I
Alport I
syndrome I
is O
a O
progressive O
hematuric B
glomerulonephritis I
characterized O
by O
glomerular B
basement I
membrane I
abnormalities I
and O
associated O
with O
mutations O
in O
either O
the O
COL4A3 O
or O
the O
COL4A4 O
gene O
, O
which O
encode O
the O
alpha3 O
and O
alpha4 O
type O
IV O
collagen O
chains O
, O
respectively O
. O

We O
report O
here O
the O
complete O
characterization O
of O
the O
48 O
exons O
of O
the O
COL4A4 O
gene O
, O
a O
comprehensive O
gene O
screen O
, O
and O
the O
subsequent O
detection O
of O
10 O
novel O
mutations O
in O
eight O
patients O
diagnosed O
with O
autosomal B
recessive I
Alport I
syndrome I
. O

Founder O
BRCA1 O
and O
BRCA2 O
mutations O
in O
French O
Canadian O
breast B
and I
ovarian I
cancer I
families O
. O

We O
have O
identified O
four O
mutations O
in O
each O
of O
the O
breast B
cancer I
- O
susceptibility O
genes O
, O
BRCA1 O
and O
BRCA2 O
, O
in O
French O
Canadian O
breast B
cancer I
and O
breast B
/ I
ovarian I
cancer I
families O
from O
Quebec O
. O

The O
identification O
of O
common O
BRCA1 O
and O
BRCA2 O
mutations O
will O
facilitate O
carrier O
detection O
in O
French O
Canadian O
breast B
cancer I
and O
breast B
/ I
ovarian I
cancer I
families O
. O

Hereditary B
coproporphyria I
( O
HCP B
) O
is O
an O
autosomal B
dominant I
disease I
characterized O
by O
a O
deficiency B
of I
coproporphyrinogen I
oxidase I
( O
CPO O
) O
caused O
by O
a O
mutation O
in O
the O
CPO O
gene O
. O

Bipolar B
affective I
disorder I
( O
BPAD B
; O
manic B
- I
depressive I
illness I
) O
is O
characterized O
by O
episodes O
of O
mania B
and O
/ O
or O
hypomania B
interspersed O
with O
periods O
of O
depression B
. O

Heterozygous O
germ O
- O
line O
mutations O
in O
the O
DNA O
mismatch O
repair O
genes O
lead O
to O
hereditary B
nonpolyposis I
colorectal I
cancer I
. O

We O
have O
identified O
three O
offspring O
in O
a O
hereditary B
nonpolyposis I
colorectal I
cancer I
family O
who O
developed O
hematological B
malignancy I
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
neurofibromatosis B
type I
1 I
( O
NF1 B
) O
. O

Mutations O
of O
the O
human O
PAX6 O
gene O
underlie O
aniridia B
( O
congenital B
absence I
of I
the I
iris I
) O
, O
a O
rare O
dominant O
malformation B
of I
the I
eye I
. O

Our O
results O
support O
the O
hypothesis O
that O
the O
under O
- O
representation O
of O
missense O
mutations O
is O
caused O
by O
ascertainment O
bias O
and O
suggest O
that O
a O
substantial O
burden O
of O
PAX6 B
- I
related I
disease I
remains O
to O
be O
uncovered O
. O
. O

Germ O
- O
line O
and O
somatic O
truncating O
mutations O
of O
the O
APC B
gene O
are O
thought O
to O
initiate O
colorectal B
tumor I
formation O
in O
familial B
adenomatous I
polyposis I
syndrome I
and O
sporadic O
colorectal O
carcinogenesis O
, O
respectively O
. O

Although O
the O
link O
between O
the O
BRCA1 O
tumour B
- O
suppressor O
gene O
and O
hereditary B
breast I
and I
ovarian I
cancer I
is O
established O
, O
the O
role O
, O
if O
any O
, O
of O
BRCA1 O
in O
non B
- I
familial I
cancers I
is O
unclear O
. O

